NCT03356834View on ClinicalTrials.gov

Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF

PHASE4CompletedINTERVENTIONAL

Enrollment

575

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Chronic Hepatitis B

Interventions

DRUG

Tenofovir alafenamide(TAF)

25 mg tablet administered orally once daily

DRUG

Tenofovir disoproxil fumarate(TDF)

300 mg tablet administered orally once daily

Trial Locations (1)

00852

Humanity and Health GI and Liver Centre, Hong Kong

All Listed Sponsors

lead

Humanity and Health Research Centre

OTHER

NCT03356834 - Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF | Biotech Hunter | Biotech Hunter